Cyproheptadine exhibits antitumor activity in urothelial carcinoma cells by targeting GSK3β to suppress mTOR and β-catenin signaling pathways

Cancer Letters

Volumn 370, Issue 1, 2016, Pages 56-65

  Hsieh, Hsiao Yen ^a,b   Shen, Cheng Huang ^a   Lin, Ru Inn ^c   Feng, Yu Min ^a,f   Huang, Shih Yuan ^b   Wang, Yuan Hung ^d,e   Wu, Shu Fen ^b   Hsu, Cheng Da ^a,b   Chan, Michael W Y ^a,b  

^a CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^b NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f Health Science and Management   (Taiwan)

Author keywords

ANGPTL4; Cyproheptadine; mTOR signaling; Urothelial carcinoma; Wnt catenin signaling

Indexed keywords

BETA CATENIN; CASPASE 3; CYPROHEPTADINE; GLYCOGEN SYNTHASE KINASE 3BETA; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P21; PROTEIN P27; RETINOBLASTOMA PROTEIN; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; TUBERIN; ANGIOPOIETIN; ANGPTL4 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; CTNNB1 PROTEIN, HUMAN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MTOR PROTEIN, HUMAN; SEROTONIN RECEPTOR; TARGET OF RAPAMYCIN KINASE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER CELL LINE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG TARGETING; ENZYME ACTIVATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DRUG EFFECTS; GENETICS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; URINARY BLADDER NEOPLASMS;

ANGIOPOIETINS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA CATENIN; CELL LINE, TUMOR; CYPROHEPTADINE; G1 PHASE CELL CYCLE CHECKPOINTS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MICE; MICE, INBRED BALB C; RECEPTORS, SEROTONIN; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 84949456367     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.09.018     Document Type: Article

References (49)

1. Chen C.H., Yang H.J., Shun C.T., Huang C.Y., Huang K.H., Yu H.J., et al. A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer. Urol. Oncol 2012, 30:421-427.
2. Schmelzle T., Hall M.N. TOR, a central controller of cell growth. Cell 2000, 103:253-262.
3. Gingras A.C., Raught B., Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001, 15:807-826.
4. Gordan J.D., Thompson C.B., Simon M.C. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 2007, 12:108-113.
5. Ching C.B., Hansel D.E. Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway. Lab. Invest 2010, 90:1406-1414.
6. Garcia J.A., Danielpour D. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol. Cancer Ther 2008, 7:1347-1354.
7. Mansure J.J., Nassim R., Chevalier S., Rocha J., Scarlata E., Kassouf W. Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer Biol. Ther 2009, 8:2339-2347.
8. Klein G.L., Galant S.P. A comparison of the antipruritic efficacy of hydroxyzine and cyproheptadine in children with atopic dermatitis. Ann. Allergy 1980, 44:142-145.
9. Kardinal C.G., Loprinzi C.L., Schaid D.J., Hass A.C., Dose A.M., Athmann L.M., et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990, 65:2657-2662.
10. Rao B.S., Das D.G., Taraknath V.R., Sarma Y. A double blind controlled study of propranolol and cyproheptadine in migraine prophylaxis. Neurol. India 2000, 48:223-226.
11. Mao X., Liang S.B., Hurren R., Gronda M., Chow S., Xu G.W., et al. Cyproheptadine displays preclinical activity in myeloma and leukemia. Blood 2008, 112:760-769.
12. Feng Y.M., Feng C.W., Chen S.C., Hsu C.D. Unexpected remission of hepatocellular carcinoma (HCC) with lung metastasis to the combination therapy of thalidomide and cyproheptadine: report of two cases and a preliminary HCC cell line study. BMJ Case Rep 2012, 2012. 10.1136/bcr-2012-007180.
13. Feng Y.M., Feng C.W., Chen S.Y., Hsieh H.Y., Chen Y.H., Hsu C.D. Cyproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase. BMC Cancer 2015, 15:134.
14. Li J., Cao B., Zhou S., Zhu J., Zhang Z., Hou T., et al. Cyproheptadine-induced myeloma cell apoptosis is associated with inhibition of the PI3K/AKT signaling. Eur. J. Haematol 2013, 91:514-521.
15. MacDonald B.T., Tamai K., He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell 2009, 17:9-26.
16. Lin C., Yin Y., Stemler K., Humphrey P., Kibel A.S., Mysorekar I.U., et al. Constitutive beta-catenin activation induces male-specific tumorigenesis in the bladder urothelium. Cancer Res 2013, 73:5914-5925.
17. Inoki K., Ouyang H., Zhu T., Lindvall C., Wang Y., Zhang X., et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006, 126:955-968.
18. Jansson E.A., Are A., Greicius G., Kuo I.C., Kelly D., Arulampalam V., et al. The Wnt/beta-catenin signaling pathway targets PPARgamma activity in colon cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:1460-1465.
19. Liu J., Wang H., Zuo Y., Farmer S.R. Functional interaction between peroxisome proliferator-activated receptor gamma and beta-catenin. Mol. Cell. Biol 2006, 26:5827-5837.
20. Yoon J.C., Chickering T.W., Rosen E.D., Dussault B., Qin Y., Soukas A., et al. Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation. Mol. Cell. Biol 2000, 20:5343-5349.
21. Ng K.T., Xu A., Cheng Q., Guo D.Y., Lim Z.X., Sun C.K., et al. Clinical relevance and therapeutic potential of angiopoietin-like protein 4 in hepatocellular carcinoma. Mol. Cancer 2014, 13:196.
22. Sherr C.J. Cancer cell cycles. Science 1996, 274:1672-1677.
23. Vermeulen K., Berneman Z.N., Van Bockstaele D.R. Cell cycle and apoptosis. Cell Prolif 2003, 36:165-175.
24. Chen M., Cassidy A., Gu J., Delclos G.L., Zhen F., Yang H., et al. Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis 2009, 30:2047-2052.
25. Jungwirth N., Haeberle L., Schrott K.M., Wullich B., Krause F.S. Serotonin used as prognostic marker of urological tumors. World J. Urol 2008, 26:499-504.
26. Siddiqui E.J., Shabbir M.A., Mikhailidis D.P., Mumtaz F.H., Thompson C.S. The effect of serotonin and serotonin antagonists on bladder cancer cell proliferation. BJU Int 2006, 97:634-639.
27. Graudins A., Stearman A., Chan B. Treatment of the serotonin syndrome with cyproheptadine. J. Emerg. Med 1998, 16:615-619.
28. Murray K.C., Nakae A., Stephens M.J., Rank M., D'Amico J., Harvey P.J., et al. Recovery of motoneuron and locomotor function after spinal cord injury depends on constitutive activity in 5-HT2C receptors. Nat. Med 2010, 16:694-700.
29. Honrubia M.A., Rodriguez J., Dominguez R., Lozoya E., Manaut F., Seijas J.A., et al. Synthesis, affinity at 5-HT2A, 5-HT2B and 5-HT2C serotonin receptors and structure-activity relationships of a series of cyproheptadine analogues. Chem. Pharm. Bull 1997, 45:842-848.
30. Lin H.Y., Hung S.K., Lee M.S., Chiou W.Y., Huang T.T., Tseng C.E., et al. DNA methylome analysis identifies epigenetic silencing of FHIT as a determining factor for radiosensitivity in oral cancer: an outcome-predicting and treatment-implicating study. Oncotarget 2015, 6:915-934.
31. Willert K., Shibamoto S., Nusse R. Wnt-induced dephosphorylation of axin releases beta-catenin from the axin complex. Genes Dev 1999, 13:1768-1773.
32. Shtutman M., Zhurinsky J., Simcha I., Albanese C., D'Amico M., Pestell R., et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:5522-5527.
33. Sabatino L., Pancione M., Votino C., Colangelo T., Lupo A., Novellino E., et al. Emerging role of the beta-catenin-PPARgamma axis in the pathogenesis of colorectal cancer. World J. Gastroenterol 2014, 20:7137-7151.
34. Paoluzzi L., Scotto L., Marchi E., Seshan V.E., O'Connor O.A. The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor. Br. J. Haematol 2009, 146:656-659.
35. Obaya A.J., Kotenko I., Cole M.D., Sedivy J.M. The proto-oncogene c-myc acts through the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1) to facilitate the activation of Cdk4/6 and early G(1) phase progression. J. Biol. Chem 2002, 277:31263-31269.
36. Mukhopadhyay I., Sausville E.A., Doroshow J.H., Roy K.K. Molecular mechanism of adaphostin-mediated G1 arrest in prostate cancer (PC-3) cells: signaling events mediated by hepatocyte growth factor receptor, c-Met, and p38 MAPK pathways. J. Biol. Chem 2006, 281:37330-37344.
37. Akiyama T., Ohuchi T., Sumida S., Matsumoto K., Toyoshima K. Phosphorylation of the retinoblastoma protein by cdk2. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:7900-7904.
38. Connell-Crowley L., Harper J.W., Goodrich D.W. Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol. Biol. Cell 1997, 8:287-301.
39. Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993, 75:805-816.
40. Abbas T., Dutta A. p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 2009, 9:400-414.
41. Tetsu O., McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999, 398:422-426.
42. Naito S., Bilim V., Yuuki K., Ugolkov A., Motoyama T., Nagaoka A., et al. Glycogen synthase kinase-3beta: a prognostic marker and a potential therapeutic target in human bladder cancer. Clin. Cancer Res 2010, 16:5124-5132.
43. Tan M.J., Teo Z., Sng M.K., Zhu P., Tan N.S. Emerging roles of angiopoietin-like 4 in human cancer. Mol. Cancer Res 2012, 10:677-688.
44. Galaup A., Cazes A., Le Jan S., Philippe J., Connault E., Le Coz E., et al. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:18721-18726.
45. Jiang B.H., Liu L.Z. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist. Updat 2008, 11:63-76.
46. Yuan T.L., Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510.
47. Memmott R.M., Dennis P.A. Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell. Signal 2009, 21:656-664.
48. Amit S., Hatzubai A., Birman Y., Andersen J.S., Ben-Shushan E., Mann M., et al. Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev 2002, 16:1066-1076.
49. Liu C., Li Y., Semenov M., Han C., Baeg G.H., Tan Y., et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002, 108:837-847.